Genmab A/S ADS (GMAB)
Nasdaq · American depositary receipt
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow GMAB in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on GMAB and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
GMAB at a glance
Key statistics
$24.02B
Market capitalization
- Previous close
- $39.07
- Open
- $39.06
- Day range
- $39.05 – $39.62
- Volume
- 1.91M
- Average volume (30 sessions)
- 3.61M
- Shares outstanding
- 624.06M
- Beta (1 year, vs SPY)
- 0.82
Where the price sits in its year
52-week range
96% of the range
- Below the 52-week high
- -1.7%
- Above the 52-week low
- +67.2%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $36.50+7.0%
- 50-day average
- $34.62+12.8%
- 200-day average
- $29.94+30.5%
Between the conventional 30 and 70 bands.
+6.8%
1 week
+12.6%
1 month
+35.4%
3 months
+26.9%
Year to date
+17.8%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with GMAB
GMAB on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on GMAB.
See the plans →
Every planScreen names like GMAB
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on GMAB
Put GMAB on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on GMAB
See whether there is an open premium alert on GMAB, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
GMAB headlines
- Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
GlobeNewswire Inc. · Oct 5, 2026
- Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
GlobeNewswire Inc. · Oct 3, 2026
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
GlobeNewswire Inc. · Sep 24, 2026
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
GlobeNewswire Inc. · Sep 8, 2026
- Genmab to Participate in Upcoming Investor Conferences
GlobeNewswire Inc. · Aug 25, 2026
- Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
GlobeNewswire Inc. · Jul 23, 2026
- Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
GlobeNewswire Inc. · Jul 6, 2026
- Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
GlobeNewswire Inc. · Jun 13, 2026
SEC Form 4, most recent first
Insider filings
No insider transactions reported for GMAB recently. ETFs and many foreign issuers do not file Form 4.
About Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
- Exchange
- Nasdaq
- Security
- American depositary receipt
- Employees
- 3,119
- Listed since
- Oct 5, 2010
- Website
- genmab.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.